Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Piani, F; Sasai, F; Bjornstad, P; Borghi, C; Yoshimura, A; Sanchez-Lozada, LG; Roncal-Jimenez, C; Garcia, GE; Hernando, AA; Fuentes, GC; Rodriguez-Iturbe, B; Lanaspa, MA; Johnson, RJ.
Hyperuricemia and chronic kidney disease: to treat or not to treat.
J Bras Nefrol. 2021; 43(4):572-579
Doi: 10.1590/2175-8239-JBN-2020-U002
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
- Autor*innen der Med Uni Graz:
- Piani Federica
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Hyperuricemia is common in chronic kidney disease (CKD) and may be present in 50% of patients presenting for dialysis. Hyperuricemia can be secondary to impaired glomerular filtration rate (GFR) that occurs in CKD. However, hyperuricemia can also precede the development of kidney disease and predict incident CKD. Experimental studies of hyperuricemic models have found that both soluble and crystalline uric acid can cause significant kidney damage, characterized by ischemia, tubulointerstitial fibrosis, and inflammation. However, most Mendelian randomization studies failed to demonstrate a causal relationship between uric acid and CKD, and clinical trials have had variable results. Here we suggest potential explanations for the negative clinical and genetic findings, including the role of crystalline uric acid, intracellular uric acid, and xanthine oxidase activity in uric acid-mediated kidney injury. We propose future clinical trials as well as an algorithm for treatment of hyperuricemia in patients with CKD.
- Find related publications in this database (using NLM MeSH Indexing)
- Glomerular Filtration Rate - administration & dosage
- Humans - administration & dosage
- Hyperuricemia - complications
- Renal Dialysis - administration & dosage
- Renal Insufficiency, Chronic - complications, therapy
- Uric Acid - administration & dosage